Rating Watching: Is Benchmark Positive For Heska (NASDAQ:HSKA)?

November 29, 2016 - By Winifred Garcia

Rating Watching: Is Benchmark Positive For Heska (NASDAQ:HSKA)?

Why Benchmark Gives Heska (NASDAQ:HSKA) $78.00 Price Target

In a analysts note issued to clients on Tuesday, 29 November, Benchmark analyst just has started coverage of Heska (NASDAQ:HSKA) with “Buy” rating. The target price per share is set to $78.00.

Heska Corp (NASDAQ:HSKA) Ratings Coverage

Out of 2 analysts covering Heska Corp (NASDAQ:HSKA), 0 rate it a “Buy”, 0 “Sell”, while 2 “Hold”. This means 0 are positive. Heska Corp has been the topic of 3 analyst reports since August 25, 2015 according to StockzIntelligence Inc. The rating was downgraded by Gabelli on Thursday, August 4 to “Hold”. The stock has “Neutral” rating given by CL King on Friday, April 1. TheStreet upgraded the shares of HSKA in a report on Tuesday, August 25 to “Hold” rating.

About 55,834 shares traded hands. Heska Corp (NASDAQ:HSKA) has risen 132.87% since April 26, 2016 and is uptrending. It has outperformed by 127.61% the S&P500.

Analysts await Heska Corp (NASDAQ:HSKA) to report earnings on March, 2. They expect $0.37 EPS, up 32.14% or $0.09 from last year’s $0.28 per share. HSKA’s profit will be $2.52 million for 45.18 P/E if the $0.37 EPS becomes a reality. After $0.45 actual EPS reported by Heska Corp for the previous quarter, Wall Street now forecasts -17.78% negative EPS growth.

Insitutional Activity: The institutional sentiment decreased to 1.36 in Q2 2016. Its down 0.18, from 1.54 in 2016Q1. The ratio dived, as 6 funds sold all Heska Corp shares owned while 29 reduced positions. 24 funds bought stakes while 30 increased positions. They now own 4.56 million shares or 4.63% more from 4.36 million shares in 2016Q1.

Credit Suisse Ag last reported 0.02% of its portfolio in the stock. Renaissance Technology Ltd last reported 0.01% of its portfolio in the stock. Deutsche Natl Bank Ag holds 0% or 976 shares in its portfolio. Cornerstone Management Hldgs Limited Liability holds 0.01% or 25,073 shares in its portfolio. Commercial Bank Of Ny Mellon Corp has 0% invested in the company for 79,633 shares. Amer Century holds 0% or 9,474 shares in its portfolio. Legal General Public Ltd Company last reported 0% of its portfolio in the stock. Adams Diversified Equity Fund Incorporated has 0.02% invested in the company for 7,500 shares. Blackrock reported 5,095 shares or 0% of all its holdings. The Texas-based Eagle Global Advsrs Ltd Liability has invested 0.02% in Heska Corp (NASDAQ:HSKA). Globeflex Limited Partnership owns 4,028 shares or 0.04% of their US portfolio. Moreover, Bancorporation Of America De has 0% invested in Heska Corp (NASDAQ:HSKA) for 35,844 shares. Bnp Paribas Arbitrage holds 241 shares or 0% of its portfolio. Royal Financial Bank Of Canada holds 0% or 380 shares in its portfolio. Jpmorgan Chase And has invested 0% of its portfolio in Heska Corp (NASDAQ:HSKA).

Insider Transactions: Since July 1, 2016, the stock had 0 insider buys, and 15 insider sales for $6.68 million net activity. Wilson Kevin S. also sold $879 worth of Heska Corp (NASDAQ:HSKA) shares. 5,000 shares with value of $305,000 were sold by Asakowicz Steve on Monday, November 7. McMahon John had sold 137 shares worth $7,028 on Wednesday, August 24. The insider NAPOLITANO JASON A sold $262,642. On Tuesday, November 22 Lippincott Rod sold $324,258 worth of the stock or 5,000 shares. Shares for $601,051 were sold by McGinley Michael J on Monday, November 7.

Heska Corporation develops, manufactures, markets, sells and supports veterinary products. The company has a market cap of $456.26 million. The Firm focuses on the canine and feline companion animal health markets. It has a 53.82 P/E ratio. The Company’s divisions include Core Companion Animal Health segment, which includes, primarily for canine and feline use, blood testing instruments and supplies, digital imaging products, software and services, and single use services and products, such as heartworm diagnostic tests, heartworm preventive products, allergy immunotherapy products and allergy testing, and Other Vaccines, Pharmaceuticals and Products segment, which includes private label vaccine and pharmaceutical production, primarily for cattle but also for other animals, including small mammals.

According to Zacks Investment Research, “Heska Corporation is focused on the discovery, development and marketing of companion animal health products. In addition to manufacturing certain of companion animal products, the company’s primary manufacturing subsidiary, Diamond Animal Health, Inc., also manufactures animal health vaccine products which are marketed and distributed by third parties. In addition to manufacturing veterinary allergy products for marketing and sale by the company, subsidiaries, Center Laboratories, Inc. and CMG-Heska Allergy Products S.A., also manufacture and sell human allergy products.”

HSKA Company Profile

Heska Corporation, incorporated on March 27, 1997, develops, makes, markets, sells and supports veterinary products. The Firm is focused on the canine and feline companion animal health markets. The Firm operates in two divisions, which include Core Companion Animal Health (CCA) and Other Vaccines, Pharmaceuticals and Products (OVP). The CCA segment includes, primarily for canine and feline use, blood testing instruments and supplies, digital imaging products, software and services, and single use services and products, such as heartworm diagnostic tests, heartworm preventive products, allergy immunotherapy products and allergy testing. The OVP segment includes private label vaccine and pharmaceutical production, primarily for cattle but also for other animals, including small mammals. It sells veterinary diagnostic and other specialty veterinary products. The Company’s offerings include blood testing instruments and supplies, digital imaging products, software and services, and single use services and products, such as in-clinic heartworm diagnostic tests, heartworm preventive products, allergy immunotherapy products and allergy testing.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Tags: , ,

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>